| Literature DB >> 32562362 |
Elena Nikiphorou1, Sofia Ramiro2, Alexandre Sepriano3, Adeline Ruyssen-Witrand4, Robert B M Landewé5, Désirée van der Heijde6.
Abstract
OBJECTIVE: To investigate the relationship between smoking and imaging outcomes over 5 years in axial spondyloarthritis (SpA) and to assess whether socioeconomic factors influence these relationships.Entities:
Year: 2020 PMID: 32562362 PMCID: PMC7702033 DOI: 10.1002/art.41408
Source DB: PubMed Journal: Arthritis Rheumatol ISSN: 2326-5191 Impact factor: 10.995
Baseline characteristics of the study patients (n = 406)*
| Baseline | 5 years | |
|---|---|---|
| Independent variable | ||
| Age, years | 31.6 ± 7.3 | – |
| Male sex, no. (%) | 210 (52) | – |
| Current smoker, no. (%) | 162 (40) | – |
| White ethnicity, no. (%) | 363 (89) | – |
| Low education level (primary/secondary school), no. (%) | 145 (36) | – |
| Blue‐collar profession (n = 351), no. (%) | 64 (18) | – |
| Married/in couple, no. (%) | 251 (62) | – |
| No. of children | 0.91 ± 1.1 | – |
| HLA–B27 positive, no. (%) | 358 (88) | – |
| Symptom duration, years | 1.6 ± 0.9 | – |
| ASDAS‐CRP (n = 391) | 2.6 ± 1.0 | – |
| CRP, mg/liter (n = 395) | 8.5 ± 13.7 | – |
| BASDAI, 0–10 (n = 405) | 4.2 ± 2.0 | – |
| BASFI, 0–10 (n=403) | 2.8 ± 2.2 | – |
| History of uveitis, no. (%) | 39 (10) | – |
| History of psoriasis, no. (%) | 60 (15) | – |
| History of IBD, no. (%) | 20 (5) | – |
| History of peripheral arthritis, no. (%) | 91 (22) | – |
| NSAID score in past week, 0–400 (n = 397) | 61.9 ± 52.3 | – |
| TNFi use, no. (%) | 0 (0) | – |
| Imaging outcome | ||
|
Spine radiograph, mSASSS score, 0–72 (n = 389 at baseline, n = 251 at 5 years) | 0.4 ± 1.7 | 1.0 ± 3.7 |
|
SI joint radiograph, modified New York score, 0–8 (n = 396 at baseline, n = 269 at 5 years) | 1.7 ± 1.8 | 2.0 ± 2.0 |
|
Spine MRI, SPARCC score, 0–414 (n = 383 at baseline, n = 100 at 5 years) | 2.7 ± 8.0 | 2.2 ± 4.6 |
|
SI joint MRI, SPARCC score, 0–72 (n = 391 at baseline, n = 100 at 5 years) | 4.5 ± 7.6 | 3.1 ± 5.5 |
Except where indicated otherwise, values are the mean ± SD. ASDAS‐CRP = Ankylosing Spondylitis Disease Activity Score using the C‐reactive protein level; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; IBD = inflammatory bowel disease; NSAID = nonsteroidal antiinflammatory drug; TNFi = tumor necrosis factor inhibitor; mSASSS = modified Stoke Ankylosing Spondylitis Spine Score; SI = sacroiliac; MRI = magnetic resonance imaging; SPARCC = Spondyloarthritis Research Consortium of Canada.
Association (β [95% confidence interval]) between baseline smoking and imaging outcomes at each visit during 5‐year follow‐up*
| Spine radiograph, mSASSS score, | SI joint radiograph, modified New York score, |
Spine MRI, SPARCC score, |
SI joint MRI, SPARCC score | ||
|---|---|---|---|---|---|
|
all patients (n = 331) |
all patients (n = 328) |
all patients (n = 377) |
Blue‐collar patients (n = 55) |
White‐collar patients (n = 264) | |
| Smoking vs. not smoking | 0.26 (−0.35, 0.86) | 0.57 (0.18, 0.96) | 1.69 (0.45, 2.93) | 5.41 (1.35, 9.48) | 0.24 (−1.13,1.62) |
| Age | 0.06 (0.01, 0.11) | −0.03 (−0.06, 0.00) | 0.07 (−0.03, 0.17) | −0.05 (−0.32, 0.21) | −0.13 (−0.24, −0.02) |
| Male vs. female | 0.36 (−0.18, 0.89) | 0.25 (−0.12, 0.63) | 2.39 (1.29, 3.49) | 3.80 (0.15, 7.45) | 2.07 (0.68, 3.47) |
| White ethnicity vs. all other ethnic groups |
| −1.03 (−1.75, −0.30) |
|
|
|
| Blue‐collar vs. white‐collar | 0.70 (−0.13, 1.54) | 0.75 (0.24, 1.75) |
|
|
|
| Abnormal vs. normal CRP level | 0.70 (−0.13, 1.54) | 1.23 (0.77, 1.69) | 4.29 (2.28, 6.31) | 7.41 (1.90,12.92) | 3.47 (1.63, 5.31) |
| BASDAI (0–10) |
| −0.16 (−0.25, −0.07) |
| −1.08 (−2.16, −0.00)§ | −0.27 (−0.66, 0.12) |
| csDMARD use in last 6 months vs. not |
| −0.75 (−1.28, −0.22) | −2.39 (−3.79, −0.99) | −4.29 (−7.54, −1.03) | −2.41 (−4.17, −0.65) |
| Presence of uveitis |
|
| −1.97 (−3.24, −0.69) |
|
|
| Presence of peripheral arthritis |
|
| −2.32 (−3.54, −1.10) | −6.52 (−10.03, −3.00) | −1.67 (−4.09, 0.74) |
Stratified models for SI joint MRI (SPARCC score) are shown due to identified interactions between smoking and job type. Other independent variables tested (P > 0.20 in univariable models) include HLA–B27 status, all socioeconomic variables of interest, ASDAS or BASDAI, and presence of psoriasis or IBD. csDMARD = conventional synthetic disease‐modifying antirheumatic drug (see Table 1 for other definitions).
P < 0.05.
Not significant in multivariable models.
Confounding effect on the association between smoking and the outcome.
Figure 1Effect of baseline smoking on magnetic resonance imaging–detected sacroiliac joint inflammation at each visit during the 5 years of follow‐up in axial spondyloarthritis patients with blue‐collar jobs compared to those with white‐collar jobs at baseline. Values in parentheses are the 95% confidence interval.
Association between baseline smoking and SI joint MRI results (SPARCC score) at each visit, in models stratified by level of education*
| SI joint MRI, SPARCC score, β (95% CI) | ||
|---|---|---|
|
Lower education (n = 134) |
Higher education (n = 248) | |
| Smoking vs. not smoking | 2.65 (0.42, 4.88) | 0.36 (−1.00, 1.71) |
| Age | 0.05 (−0.09, 0.19) | −0.11 (−0.20, −0.02) |
| Male vs. female | 3.08 (1.27, 4.90) | 1.15 (−0.18, 2.48) |
| White ethnicity vs. all other ethnic groups | −6.17 (−11.08, −1,25) | 0.09 (−2.01, 2.19) |
| Abnormal vs. normal CRP level | 4.45 (1.72, 7.18) | 2.96 (1.13, 4.80) |
| BASDAI (0–10) | −1.04 (−1.65, −0.43) | −0.38 (−0.74, −0.03) |
| csDMARD use in last 6 months vs. not | −3.79 (−6.16, −1.43) | −2.63 (−4.36, −0.90) |
Other independent variables tested in models included HLA–B27 status, all socioeconomic variables of interest, ASDAS, presence of psoriasis, IBD, or peripheral arthritis, and use of TNFi. csDMARD = conventional synthetic disease‐modifying antirheumatic drug (see Table 1 for other definitions).
P < 0.05.
Confounding effect on the association between smoking and the outcome.